Detalhe da pesquisa
1.
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Clin Chem Lab Med
; 59(12): 1963-1971, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392637
2.
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.
Haematologica
; 105(6): e302-e306, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558675
3.
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.
Blood Adv
; 5(23): 5128-5139, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625791
4.
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Oncotarget
; 11(45): 4076-4081, 2020 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33227097
5.
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients.
J Transl Autoimmun
; 2: 100022, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32743508
6.
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
Clin Lymphoma Myeloma Leuk
; 19(1): e9-e11, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30392824